LPWM
VNDA icon

Lake Point Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Lake Point Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-460
Closed -$5K – 515
2022
Q1 		$5K Hold
460
– – ﹤0.01% 248
2021
Q4 		$7K Hold
460
– – ﹤0.01% 232
2021
Q3 		$8K Buy
+460
New +$8.06K ﹤0.01% 195

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lake Point Wealth Management's VNDA Position: Q2 2022 in Review

Lake Point Wealth Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2022, closing a stake of 460 shares — an estimated $5K sold.

Lake Point Wealth Management first reported a position in VNDA in Q3 2021 and held it in 3 quarters. The position peaked at $8K in Q3 2021. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2022.

  • Lake Point Wealth Management reported no remaining Vanda Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Lake Point Wealth Management sold 460 Vanda Pharmaceuticals shares in Q2 2022, an estimated $5K.
  • Lake Point Wealth Management first reported a position in Vanda Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Lake Point Wealth Management's Vanda Pharmaceuticals position peaked at $8K in Q3 2021.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2022.

Based on Lake Point Wealth Management's 13F filing for Q2 2022, filed 19 Jul 2022.